TY - JOUR
T1 - Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow–derived multipotent mesenchymal stromal cell expansion cultures
AU - GRAU-VORSTER, MARTA
AU - RODRÍGUEZ, LUCIANO
AU - TORRENTS-ZAPATA, SÍLVIA
AU - VIVAS, DANIEL
AU - CODINACH, MARGARITA
AU - BLANCO, MARGARITA
AU - OLIVER-VILA, IRENE
AU - García López, Joan
AU - VIVES, JOAQUIM
N1 - Copyright © 2018 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - © 2018 International Society for Cellular Therapy Background aims: Multipotent mesenchymal stromal cell (MSC)-based medicines are extensively investigated for use in regenerative medicine and immunotherapy applications. The International Society for Cell and Gene Therapy (ISCT) proposed a panel of cell surface molecules for MSC identification that includes human leukocyte antigen (HLA)-DR as a negative marker. However, its expression is largely unpredictable despite production under tightly controlled conditions and compliance with current Good Manufacturing Practices. Herein, we report the frequency of HLA-DR expression in 81 batches of clinical grade bone marrow (BM)-derived MSCs and investigated its impact on cell attributes and culture environment. Methods: The levels of 15 cytokines (interleukin [IL]-1β IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interferon-γ soluble CD40 ligand and tumor necrosis factor-α) were determined in sera supplements and supernatants of BM-MSC cultures. Identity, multipotentiality and immunopotency assays were performed on high (>20% of cells) and low (≤20% of cells) HLA-DR+ cultures. Results: A correlation was found between HLA-DR expression and levels of IL-17F and IL-33. Expression of HLA-DR did neither affect MSC identity, in vitro tri-lineage differentiation potential (into osteogenic, chondrogenic and adipogenic lineages), nor their ability to inhibit the proliferation of stimulated lymphocytes. Discussion: Out of 81 batches of BM-MSCs for autologous use analyzed, only three batches would have passed the ISCT criteria (<2%), whereas 60.5% of batches were compliant with low HLA-DR values (≤20%). Although a cause–effect relationship cannot be drawn, we have provided a better understanding of signaling events and cellular responses in expansion culture conditions relating with HLA-DR expression.
AB - © 2018 International Society for Cellular Therapy Background aims: Multipotent mesenchymal stromal cell (MSC)-based medicines are extensively investigated for use in regenerative medicine and immunotherapy applications. The International Society for Cell and Gene Therapy (ISCT) proposed a panel of cell surface molecules for MSC identification that includes human leukocyte antigen (HLA)-DR as a negative marker. However, its expression is largely unpredictable despite production under tightly controlled conditions and compliance with current Good Manufacturing Practices. Herein, we report the frequency of HLA-DR expression in 81 batches of clinical grade bone marrow (BM)-derived MSCs and investigated its impact on cell attributes and culture environment. Methods: The levels of 15 cytokines (interleukin [IL]-1β IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interferon-γ soluble CD40 ligand and tumor necrosis factor-α) were determined in sera supplements and supernatants of BM-MSC cultures. Identity, multipotentiality and immunopotency assays were performed on high (>20% of cells) and low (≤20% of cells) HLA-DR+ cultures. Results: A correlation was found between HLA-DR expression and levels of IL-17F and IL-33. Expression of HLA-DR did neither affect MSC identity, in vitro tri-lineage differentiation potential (into osteogenic, chondrogenic and adipogenic lineages), nor their ability to inhibit the proliferation of stimulated lymphocytes. Discussion: Out of 81 batches of BM-MSCs for autologous use analyzed, only three batches would have passed the ISCT criteria (<2%), whereas 60.5% of batches were compliant with low HLA-DR values (≤20%). Although a cause–effect relationship cannot be drawn, we have provided a better understanding of signaling events and cellular responses in expansion culture conditions relating with HLA-DR expression.
KW - biomarker
KW - bone marrow
KW - cell culture
KW - differentiation potential
KW - good manufacturing practice
KW - HLA-DR expression
KW - immunopotency
KW - multipotent mesenchymal stromal cell
KW - Interleukin-33/blood
KW - Lymphocyte Activation
KW - Humans
KW - Mesenchymal Stem Cells/immunology
KW - Cells, Cultured
KW - Biomarkers/metabolism
KW - Primary Cell Culture/methods
KW - Interleukin-17/blood
KW - Cell Differentiation/physiology
KW - Bone Marrow/immunology
KW - HLA-DR Antigens/immunology
KW - Chondrogenesis
KW - Mesenchymal Stem Cell Transplantation
KW - Osteogenesis
KW - Adipogenesis
UR - http://www.mendeley.com/research/levels-il17f-il33-correlate-hladr-activation-clinicalgrade-human-bone-marrowderived-multipotent-mese
U2 - 10.1016/j.jcyt.2018.09.009
DO - 10.1016/j.jcyt.2018.09.009
M3 - Article
C2 - 30447901
SN - 1465-3249
VL - 21
SP - 32
EP - 40
JO - Cytotherapy
JF - Cytotherapy
ER -